"Artificial Lighthouse" Overcomes Tumor Microenvironment Heterogeneity's "Sea Fog": Pre-Targeted Strategy-Mediated Nanomedicine Enables Tumor Body Fluid Detection, In Vivo Imaging, and Multitherapy Treatment.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	"Artificial Lighthouse" Overcomes Tumor Microenvironment Heterogeneity's "Sea Fog": Pre-Targeted Strategy-Mediated Nanomedicine Enables Tumor Body Fluid Detection, In Vivo Imaging, and Multitherapy Treatment.
Συγγραφείς:	Zhang Y; Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, People's Republic of China.; Beijing Key Laboratory of Environment and Aging, Capital Medical University, Beijing, People's Republic of China., Sun Z; School of Basic Medical Sciences, Capital Medical University, Beijing, People's Republic of China., Wu D; School of Basic Medical Sciences, Capital Medical University, Beijing, People's Republic of China., Wang K; Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, People's Republic of China.; Beijing Key Laboratory of Environment and Aging, Capital Medical University, Beijing, People's Republic of China., Song H; Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China., Li Y; Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China., Cao Y; Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, People's Republic of China.; Beijing Key Laboratory of Environment and Aging, Capital Medical University, Beijing, People's Republic of China.
Πηγή:	Macromolecular bioscience [Macromol Biosci] 2026 Sep; Vol. 26 (9), pp. e70262.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101135941 Publication Model: Print Cited Medium: Internet ISSN: 1616-5195 (Electronic) Linking ISSN: 16165187 NLM ISO Abbreviation: Macromol Biosci Subsets: MEDLINE
Imprint Name(s):	Original Publication: Weinheim, Germany : Wiley-VCH, c2001-
Ιατρικοί όροι (MeSH):	Tumor Microenvironment/drug effects , Nanomedicine/methods , Neoplasms/diagnostic imaging , Neoplasms/therapy , Neoplasms/drug therapy , Body Fluids , Drug Delivery Systems*, Humans ; Animals
Περίληψη:	Nanomedicine has broad prospects in tumor diagnosis and treatment, but its clinical translation has long been limited by targeted delivery efficiency. The heterogeneity of the tumor microenvironment is like a "sea fog" that hinders precision medicine. This makes it difficult for traditional active targeting that relies on natural targets to achieve precise delivery. For this difficulty, this review summarizes the constraints of tumor microenvironment heterogeneity on nanomaterials in terms of time and space. Pre-targeting strategies enhance delivery efficiency by constructing an "artificial lighthouse." According to the source of the target and the mode of specific binding, this review divides pre-targeting strategies into two categories: biomolecular recognition-mediated and bioorthogonal click chemistry-mediated. On this basis, this review comprehensively introduces recent progress in pre-targeting-enabled nanomedicine in body fluid-based detection, in vivo imaging, and multi-therapies. Furthermore, this review is the first to summarize the synergistic mechanisms of pre-targeting with prodrugs, insitu self-assembly, and dual-targeting strategies. This review systematically summarizes the complete framework of pre-targeting strategies, from mechanisms and classifications to applications and expansions. It aims to provide inspiration for the development of nanomedicine in the field of oncology for effective cancer diagnosis and treatment. (© 2026 Wiley‐VCH GmbH.)
References:	Y. Pan, J. Cheng, Y. Zhu, J. Zhang, W. Fan, and X. Chen, “Immunological Nanomaterials to Combat Cancer Metastasis,” Chemical Society Reviews 53 (2024): 6399–6444. C. Ren, H. Zhang, M. Yang, et al., “Membrane‐Coated Hollow Manganese Nitrogen Carbon Nanocomposites Synergize Phototherapy and STING Activation for Immunogenic Tumor Microenvironment Remodeling,” ACS Applied Materials & Interfaces 17 (2025): 37053–37067. B. Wang, S. Hu, Y. Teng, et al., “Current Advance of Nanotechnology in Diagnosis and Treatment for Malignant Tumors,” Signal Transduction and Targeted Therapy 9 (2024): 200. Z. Cheng, M. Li, R. Dey, and Y. Chen, “Nanomaterials for Cancer Therapy: Current Progress and Perspectives,” Journal of Hematology & Oncology 14 (2021): 85. E. L. Yang, W. Y. Wang, Y. Q. Liu, H. Yi, A. Lei, and Z. J. Sun, “Tumor‐Targeted Catalytic Immunotherapy,” Advanced Materials 37 (2025): 2413210. R. M. Pallares, R. A. Barmin, A. Wang, F. Kiessling, and T. Lammers, “Clinical Cancer Nanomedicines,” Journal of Controlled Release 385 (2025): 113991. O. Elhanani, R. Ben‐Uri, and L. Keren, “Spatial Profiling Technologies Illuminate the Tumor Microenvironment,” Cancer Cell 41 (2023): 404–420. F. XIE, N. XI, Z. HAN, et al., “Progress in Research on Tumor Microenvironment‐based Spatial Omics Technologies,” Oncology Research 31 (2023): 877–885. A. Fomitcheva‐Khartchenko, A. Kashyap, T. Geiger, and G. V. Kaigala, “Space in Cancer Biology: Its Role and Implications,” Trends Cancer 8 (2022): 1019. A. M. Wandmacher, A. S. Mehdorn, and S. Sebens, “The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer,” Cancers (Basel) 13 (2021): 4932. H. Luo, X. Xia, L.‐B. Huang, et al., “Pan‐cancer Single‐cell Analysis Reveals the Heterogeneity and Plasticity of Cancer‐associated Fibroblasts in the Tumor Microenvironment,” Nature Communications 13 (2022): 6619. S. Lee, G. Kim, J. Lee, A. C. Lee, and S. Kwon, “Mapping Cancer Biology in Space: Applications and Perspectives on Spatial Omics for Oncology,” Molecular Cancer 23 (2024): 26. Y. Chen, K. M. McAndrews, and R. Kalluri, “Clinical and Therapeutic Relevance of Cancer‐associated Fibroblasts,” Nature Reviews Clinical Oncology 18 (2021): 792–804. M. R. Thomas, A. K. Badekila, V. Pai, et al., “Navigating Tumor Microenvironment Barriers with Nanotherapeutic Strategies for Targeting Metastasis,” Advanced Healthcare Materials 14 (2025): 2403107. M. Yang, J. Li, P. Gu, and X. Fan, “The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment,” Bioactive Materials 6 (2021): 1973. X. Yu, R. Liu, W. Gao, X. Wang, and Y. Zhang, “Single‐cell Omics Traces the Heterogeneity of Prostate Cancer Cells and the Tumor Microenvironment,” Cellular & Molecular Biology Letters 28 (2023): 38. V. I. J. Jallinoja and J. L. Houghton, “Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy,” Journal of Nuclear Medicine 62 (2021): 1200–1206. Y. Tian, Z. Huang, J. Luo, and D. Ye, “Recent Advances in Pretargeted Strategy for Cancer Theranostics,” ChemMedChem 19 (2024): 202400462. S. M. Cheal, S. K. Chung, B. A. Vaughn, N. V. Cheung, and S. M. Larson, “Pretargeting: a Path Forward for Radioimmunotherapy,” Journal of Nuclear Medicine 63 (2022): 1302–1315. E. N. Komedchikova, O. A. Kolesnikova, A. S. Obozina, et al., “It Takes Two: Advancing Cancer Treatment with Two‐step Nanoparticle Delivery,” Biochemical and Biophysical Research Communications 767 (2025): 151921. L. Taiariol, C. Chaix, C. Farre, and E. Moreau, “Click and Bioorthogonal Chemistry: the Future of Active Targeting of Nanoparticles for Nanomedicines?,” Chemical Reviews 122 (2022): 340–384. J. Y. So, J. Ohm, S. Lipkowitz, and L. Yang, “Triple Negative Breast Cancer (TNBC): Non‐genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options,” Pharmacology & Therapeutics 237 (2022): 108253. F. Wu, J. Fan, Y. He, et al., “Single‐cell Profiling of Tumor Heterogeneity and the Microenvironment in Advanced Non‐small Cell Lung Cancer,” Nature Communications 12 (2021): 2540. Y. Zhang, C. Yang, X. Chen, et al., “Cancer Therapy Resistance from a Spatial‐Omics Perspective,” Clinical and Translational Medicine 15 (2025): 70396. R. Tian, Z. Xue, Y. Chen, et al., “Integrating Cross‐sample and Cross‐modal Data for Spatial Transcriptomics and Metabolomics with SpatialMETA,” Nature Communications 16 (2025): 8855. X. Song, X. Yu, C. M. Moran‐Segura, et al., “ROICellTrack: a Deep Learning Framework for Integrating Cellular Imaging Modalities in Subcellular Spatial Transcriptomic Profiling of Tumor Tissues,” Bioinformatics 41 (2025): btaf152. A. Del Prete, V. Salvi, A. Soriani, et al., “Dendritic Cell Subsets in Cancer Immunity and Tumor Antigen Sensing,” Cell Mol Immunol 20 (2023): 432. D. Chen, X. Zhang, Z. Li, and B. Zhu, “Metabolic Regulatory Crosstalk between Tumor Microenvironment and Tumor‐associated Macrophages,” Theranostics 11 (2021): 1016–1030. S. Mei, X. Wang, M. Zhao, et al., “Resolving the Spatial and Cellular Architecture of Intra‐tumor Heterogeneity by Multi‐region Dissection of Lung Adenocarcinoma,” Journal of Genetics and Genomics 52 (2025): 1121–1132. F. Li, Y. Li, L. Wang, et al., “Tumor Microenvironment Heterogeneity and Progression Mechanisms in Intrahepatic Cholangiocarcinoma: a Study Based on Single‐cell and Spatial Transcriptomic Sequencing,” Hepatology 83 (2026): 1082–1097. C. Kalogirou, M. Krebs, A. S. Kunz, et al., “Spatial Transcriptomic Profiling of Metastatic Renal Cell Carcinoma Identifies Chemokine‐driven Macrophage and CD8+ T‐cell Interactions Predictive of Immunotherapy Response,” Journal for ImmunoTherapy of Cancer 13 (2025): 012991. X. Deng, X. Liu, and L. Zhao, “Multifunctional Nanoplatforms for Tumor Microenvironment Remodeling: Toward Precision and Intelligent Cancer Therapy,” Materials Today Bio 35 (2025): 102385. X. Dong, P. Pan, Q. Zhang, J. J. Ye, and X. Z. Zhang, “Engineered Living Bacteriophage‐Enabled Self‐Adjuvanting Hydrogel for Remodeling Tumor Microenvironment and Cancer Therapy,” Nano Letters 23 (2023): 1219–1228. P. Cantallops Vilà, A. Ravichandra, A. Agirre Lizaso, M. J. Perugorria, and S. Affò, “Heterogeneity, Crosstalk, and Targeting of Cancer‐associated Fibroblasts in Cholangiocarcinoma,” Hepatology 79 (2024): 941–958. H. Song, H. N. W. Weinstein, P. Allegakoen, et al., “Single‐cell Analysis of human Primary Prostate Cancer Reveals the Heterogeneity of Tumor‐associated Epithelial Cell States,” Nature Communications 13 (2022): 141. S. Li, J. Yu, A. Huber, et al., “Metabolism Drives Macrophage Heterogeneity in the Tumor Microenvironment,” Cell Reports 39 (2022): 110609. Z. Zhang, M. Zhai, S. Bao, et al., “Integrative Multi‐omics Profiling Deciphers Tumor Microenvironment Heterogeneity and Immunotherapy Vulnerabilities in Lung Neuroendocrine Carcinomas,” Journal of Advanced Research 81 (2026): 797–808. Y. Yang, Q. Ni, H. Li, et al., “Genomic and the Tumor Microenvironment Heterogeneity in Multifocal Hepatocellular Carcinoma,” Hepatology 82 (2025): 582–598. Y. Liu, A. Sinjab, J. Min, et al., “Conserved Spatial Subtypes and Cellular Neighborhoods of Cancer‐associated Fibroblasts Revealed by Single‐cell Spatial Multi‐omics,” Cancer Cell 43 (2025): 905–924.e6. Z. Huo, Z. Wang, H. Luo, et al., “Single‐cell Transcriptomes Reveal the Heterogeneity and Microenvironment of Vestibular Schwannoma,” Neuro‐Oncology 26 (2024): 444–457. J. Qiu, X. Qu, Y. Wang, et al., “Single‐Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus‐Associated (HPVA) and Non‐HPVA Adenocarcinoma,” Advanced Science 10 (2023): 2204951. H. J. Kim, Y. R. Ji, and Y. M. Lee, “Crosstalk between Angiogenesis and Immune Regulation in the Tumor Microenvironment,” Archives of Pharmacal Research 45 (2022): 401–416. X. Wang, Z. Wang, Q. Liao, et al., “Spatially Resolved Atlas of Breast Cancer Uncovers Intercellular Machinery of Venular Niche Governing Lymphocyte Extravasation,” Nature Communications 16 (2025): 3348. C. Feng, Y. Wang, W. Song, et al., “Spatially‐resolved Analyses of Muscle Invasive Bladder Cancer Microenvironment Unveil a Distinct Fibroblast Cluster Associated with Prognosis,” Frontiers in Immunology 15 (2024): 1522582. S. Saha, A. Bhat, S. Kukal, M. Phalak, and S. Kumar, “Spatial Heterogeneity in Glioblastoma: Decoding the Role of Perfusion,” Biochimica et Biophysica Acta (BBA) ‐ Reviews on Cancer 1880 (2025): 189383. Y. Wu, S. Li, H. Yu, et al., “Integrative Single‐Cell and Spatial Transcriptomics Analysis Reveals ECM‐remodeling Cancer‐associated Fibroblast‐Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression,” International Journal of Biological Sciences 21 (2025): 3573–3596. H. Croizer, R. Mhaidly, Y. Kieffer, et al., “Deciphering the Spatial Landscape and Plasticity of Immunosuppressive Fibroblasts in Breast Cancer,” Nature Communications 15 (2024): 2806. M. Cao, M. Long, Q. Chen, et al., “Development of β‐elemene and Cisplatin Co‐Loaded Liposomes for Effective Lung Cancer Therapy and Evaluation in Patient‐Derived Tumor Xenografts,” Pharmaceutical Research 36 (2019): 121. S. Zhou, J. Zheng, W. Zhai, and Y. Chen, “Spatio‐temporal Heterogeneity in Cancer Evolution and Tumor Microenvironment of Renal Cell Carcinoma with Tumor Thrombus,” Cancer Letters 572 (2023): 216350. S. Zhang, V. C. Jiang, G. Han, et al., “Longitudinal Single‐cell Profiling Reveals Molecular Heterogeneity and Tumor‐immune Evolution in Refractory Mantle Cell Lymphoma,” Nature Communications 12 (2021): 2877. C. Guo, X. Qu, X. Tang, et al., “Spatiotemporally Deciphering the Mysterious Mechanism of Persistent HPV‐Induced Malignant Transition and Immune Remodelling from HPV‐Infected Normal Cervix, Precancer to Cervical Cancer: Integrating Single‐Cell RNA‐Sequencing and Spatial Transcriptome,” Clinical and Translational Medicine 13 (2023): 1219. A. Zhang, K. Miao, H. Sun, and C. X. Deng, “Tumor Heterogeneity Reshapes the Tumor Microenvironment to Influence Drug Resistance,” International Journal of Biological Sciences 18 (2022): 3019–3033. A. Virtuoso, C. De Luca, G. Cirillo, et al., “Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma,” Molecular Neurobiology 59 (2022): 6857–6873. D. Lucchetti, F. Colella, A. d'Amati, et al., “Spatial Analysis Identifies CD147 as a Novel Marker of High‐Grade Childhood Posterior Fossa Ependymoma,” Laboratory Investigation 105 (2025): 104175. Z. Lin, Y. Zhou, Z. Liu, et al., “Deciphering the Tumor Immune Microenvironment: Single‐cell and Spatial Transcriptomic Insights into Cervical Cancer Fibroblasts,” Journal of Experimental & Clinical Cancer Research 44 (2025): 194. W. Xu, T. Liang, H. Fang, et al., “Single‐Cell RNA Sequencing Identifies MMP11+ Cancer‐Associated Fibroblasts as Drivers of Angiogenesis and Bladder Cancer Progression,” Advanced Science 12 (2025): 02774. X. Cui, S. Liu, H. Song, J. Xu, and Y. Sun, “Single‐cell and Spatial Transcriptomic Analyses Revealing Tumor Microenvironment Remodeling after Neoadjuvant Chemoimmunotherapy in Non‐small Cell Lung Cancer,” Molecular Cancer 24 (2025): 111. C. Wang, G. Xie, M. Jia, et al., “Single‐cell Profiling Identifies Biomarkers for Immunochemotherapy in Esophageal Squamous Cell Carcinoma,” Cancer Letters 633 (2025): 217988. Y. H. Bang, G.‐H. Park, J. W. Oh, et al., “Artificial Intelligence‐powered Spatial Analysis of Tumor Microenvironment in Patients with Non‐small Cell Lung Cancer with Acquired Resistance to EGFR Tyrosine Kinase Inhibitor,” Journal for ImmunoTherapy of Cancer 13 (2025): 012374. G.‐Q. He, S.‐J. He, X.‐Y. Jing, et al., “Dissecting Neuroblastoma Heterogeneity through Single‐cell Multi‐omics: Insights into Development, Immunity, and Therapeutic Resistance,” Oncogene 45 (2026): 123–139. R. K. Jain, “Antiangiogenesis Strategies Revisited: from Starving Tumors to Alleviating Hypoxia,” Cancer Cell 26 (2014): 605–622. Y. Huang, S. Goel, D. G. Duda, D. Fukumura, and R. K. Jain, “Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy,” Cancer Research 73 (2013): 2943–2948. D. Baimanov, J. Wang, C. Chen, and L. Wang, “Receptor Discovery for Nanomaterial Soft and Hard Coronas via a Biosensor‐based Fishing Strategy,” Nature Protocols (2026), https://doi.org/10.1038/s41596‐026‐01358‐6. D. Möckel, M. Bartneck, P. Niemietz, et al., “CCL2 chemokine Inhibition Primes the Tumor Vasculature for Improved Nanomedicine Delivery and Efficacy,” Journal of Controlled Release 365 (2024): 358. B. Zhang, Y. Hu, and Z. Pang, “Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery,” Frontiers in Pharmacology 8 (2017): 952. X. Wang, D. Venet, F. Lifrange, et al., “Spatial Transcriptomics Reveals Substantial Heterogeneity in Triple‐negative Breast Cancer with Potential Clinical Implications,” Nature Communications 15 (2024): 10232. X. Bian, W. Wang, M. Abudurexiti, et al., “Integration Analysis of Single‐Cell Multi‐Omics Reveals Prostate Cancer Heterogeneity,” Advanced Science 11 (2024): 2305724. S. Bärthel, C. Falcomatà, R. Rad, F. J. Theis, and D. Saur, “Single‐cell Profiling to Explore Pancreatic Cancer Heterogeneity, Plasticity and Response to Therapy,” Nature Cancer 4 (2023): 454–467. Y. Mori, J. Cardinale, and F. L. Giesel, “Pretargeting: Bridging the Two Worlds of Radiopharmaceutical Probes,” Clinical Cancer Research 31 (2025): 2547–2549. Q. Yang, C. L. Parker, J. D. McCallen, and S. K. Lai, “Addressing Challenges of Heterogeneous Tumor Treatment through Bispecific Protein‐mediated Pretargeted Drug Delivery,” Journal of Controlled Release 220 (2015): 715–726. D. Pan, Y. Wang, N. Xu, et al., “Feasibility of in Vivo CAR T Cells Tracking Using Streptavidin–biotin‐paired Positron Emission Tomography,” European Journal of Nuclear Medicine and Molecular Imaging 49 (2022): 4419–4426. M. Altai, Á. Nagy, P. Granit, et al., “Optimizing Peptide Nucleic Acid‐based Pretargeting for Enhanced Targeted Radionuclide Therapy,” Journal of Controlled Release 381 (2025): 113551. L. R. Ancheta, P. A. Shramm, R. Bouajram, D. Higgins, and D. A. Lappi, “Streptavidin‐Saporin: Converting Biotinylated Materials into Targeted Toxins,” Toxins (Basel) 15 (2023): 181. F. R. Sperti, T. Charbonnier, P. Lejault, et al., “Biomimetic, Smart, and Multivalent Ligands for G‐Quadruplex Isolation and Bioorthogonal Imaging,” ACS Chemical Biology 16 (2021): 905–914. M. Kincanon and C. J. Murphy, “Nanoparticle Size Influences the Self‐Assembly of Gold Nanorods Using Flexible Streptavidin–Biotin Linkages,” ACS Nano 17 (2023): 24090–24103. P. H. E. Hamming and J. Huskens, “Streptavidin Coverage on Biotinylated Surfaces,” ACS Applied Materials & Interfaces 13 (2021): 58114–58123. M. E. Goebeler, G. Stuhler, and R. Bargou, “Bispecific and Multispecific Antibodies in Oncology: Opportunities and Challenges,” Nature Reviews Clinical Oncology 21 (2024): 539–560. Y. Hong, S. M. Nam, and A. Moon, “Antibody–drug Conjugates and Bispecific Antibodies Targeting Cancers: Applications of Click Chemistry,” Archives of Pharmacal Research 46 (2023): 131–148. G. M. Gerhard and G. von Keudell, “Bispecific Antibody Therapy for Lymphoma,” Best Practice & Research Clinical Haematology 37 (2024): 101598. Y. Zhou, H. L. Penny, M. A. Kroenke, et al., “Immunogenicity Assessment of Bispecific Antibody‐based Immunotherapy in Oncology,” Journal for ImmunoTherapy of Cancer 10 (2022): 004225. M. Herrera, G. Pretelli, J. Desai, et al., “Bispecific Antibodies: Advancing Precision Oncology,” Trends in Cancer 10 (2024): 893–919. S. M. Hammond, A. Aartsma‐Rus, S. Alves, et al., “Delivery of Oligonucleotide‐Based Therapeutics: Challenges and Opportunities,” EMBO Molecular Medicine 13 (2021): 13243. H. Zhou, J. Fu, Q. Fu, et al., “Biotin‐streptavidin‐guided Two‐step Pretargeting Approach Using PLGA for Molecular Ultrasound Imaging and Chemotherapy for Ovarian Cancer,” PeerJ 9 (2021): 11486. J. P. Bost, H. Barriga, M. N. Holme, et al., “Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles,” ACS Nano 15 (2021): 13993–14021. F. Meng, J. Wang, and Y. Yeo, “Nucleic Acid and Oligonucleotide Delivery for Activating Innate Immunity in Cancer Immunotherapy,” Journal of Controlled Release 345 (2022): 586–600. B. Malecova, R. S. Burke, M. Cochran, et al., “Targeted Tissue Delivery of RNA Therapeutics Using Antibody–oligonucleotide Conjugates (AOCs),” Nucleic Acids Research 51 (2023): 5901–5910. R. Obexer, M. Nassir, E. R. Moody, P. S. Baran, and S. L. Lovelock, “Modern Approaches to Therapeutic Oligonucleotide Manufacturing,” Science 384 (2024): adl4015. V. I. J. Jallinoja, C. H. Abbriano, K. Bhatt, et al., “Pretargeting with Cucurbituril–Adamantane Host–Guest Pair in Xenograft Models,” Journal of Nuclear Medicine 64 (2023): 1203–1209. H. Hong, K. Zhou, H. Lin, Y. Li, and Z. Wu, “In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy,” Chemistry 31 (2025): 202403539. G. M. Proshkina, E. I. Shramova, A. B. Mirkasyimov, et al., “The Barnase‐Barstar‐based Pre‐targeting Strategy for Enhanced Antitumor Therapy in Vivo,” Biochimie 228 (2025): 158–166. S.‐Y. Kwon, S.‐H. You, J. H. Im, et al., “Tumor Pre‐Targeting System Using Streptavidin‐Expressing Bacteria,” Molecular Imaging and Biology 26 (2024): 593–602. N. A. Siddiqui, A. J. Ventrola, A. R. Hartman, et al., “An Engineered Probiotic Platform for Cancer Epitope‐Independent Targeted Radionuclide Therapy of Solid Tumors,” Advanced Healthcare Materials 12 (2023): 2202870. M. M. A. Mitry, F. Greco, and H. M. I. Osborn, “In Vivo Applications of Bioorthogonal Reactions: Chemistry and Targeting Mechanisms,” Chemistry 29 (2023): 202203942. H. Yang, X. Zeng, J. Liu, et al., “A Proof‐of‐concept Study on Bioorthogonal‐based Pretargeting and Signal Amplify Radiotheranostic Strategy,” Journal of Nanobiotechnology 22 (2024): 101. M. Staudt and M. M. Herth, “Clearing and Masking Agents in Pretargeting Strategies,” Pharmaceuticals 16 (2023): 497. K. Porte, M. Riberaud, R. Châtre, D. Audisio, S. Papot, and F. Taran, “Bioorthogonal Reactions in Animals,” Chembiochem 22 (2021): 100–113. R. Jamagne, M. J. Power, Z. H. Zhang, G. Zango, B. Gibber, and D. A. Leigh, “Active Template Synthesis,” Chemical Society Reviews 53 (2024): 10216–10252. S. Liu, H. Yang, X. Heng, et al., “Integrating Metabolic Oligosaccharide Engineering and SPAAC Click Chemistry for Constructing Fibrinolytic Cell Surfaces,” ACS Applied Materials & Interfaces 16 (2024): 35874–35886. X. Zhong, J. Yan, C. Su, et al., “A Novel Arene Trifluoromethyl‐Based 18 F‐Labeling Strategy for Enhanced Biomolecular Tracer Development in PET Imaging,” Molecular Pharmaceutics 22 (2025): 5860–5869. M. Handula, K. T. Chen, and Y. Seimbille, “IEDDA: an Attractive Bioorthogonal Reaction for Biomedical Applications,” Molecules 26 (2021): 4640. M. M. Welling, N. Duszenko, D. M. van Willigen, et al., “Interventional Nuclear Medicine: “Click” Chemistry as an in Vivo Targeting Strategy for Imaging Microspheres and Bacteria,” Biomaterials Science 9 (2021): 1683–1690. P. Ramírez‐López, J. R. Suárez, A. Flores, and M. J. Hernáiz, “Exploring Metal‐Free Click Reactions: New Frontiers in Glycochemistry and Bioconjugation,” Bioconjugate Chem 36 (2025): 1553. L. M. Haiber, M. Kufleitner, and V. Wittmann, “Application of the Inverse‐Electron‐Demand Diels‐Alder Reaction for Metabolic Glycoengineering,” Frontiers in Chemistry 9 (2021): 654932. Y. Deng, A. Shavandi, O. V. Okoro, and L. Nie, “Alginate Modification via Click Chemistry for Biomedical Applications,” Carbohydrate Polymers 270 (2021): 118360. F. Xie, H. Jiang, X. Jia, et al., “Bridgehead Alkene‐Enabled Strain‐Driven Bioorthogonal Reaction,” Organic Letters 24 (2022): 5304–5308. F. Xie, X. Jia, Z. Zhu, et al., “Chemical Trigger‐enabled Bioconjugation Reaction,” Organic & Biomolecular Chemistry 19 (2021): 8343–8351. K. Adhikari, M. Vanermen, G. D. Silva, T. Van den Wyngaert, K. Augustyns, and F. Elvas, “Trans‐cyclooctene—A Swiss Army Knife for Bioorthogonal Chemistry: Exploring the Synthesis, Reactivity, and Applications in Biomedical Breakthroughs,” EJNMMI Radiopharmacy and Chemistry 9 (2024): 47. B. H. Santich, S. M. Cheal, M. Ahmed, et al., “A Self‐Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two‐step Pretargeted Radioimmunotherapy,” Clinical Cancer Research 27 (2021): 532–541. S. M. Sarrett, O. Keinänen, E. J. Dayts, et al., “Inverse Electron Demand Diels–Alder Click Chemistry for Pretargeted PET Imaging and Radioimmunotherapy,” Nature Protocols 16 (2021): 3348–3381. H. Hyun, B. Sun, M. Yazdimamaghani, et al., “Tumor‐specific Surface Marker–independent Targeting of Tumors through Nanotechnology and Bioorthogonal Glycochemistry,” Journal of Clinical Investigation 135 (2025): 184964. J. Yang, K. Yang, S. Du, et al., “Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy,” Angewandte Chemie International Edition 62 (2023): 202306863. R. Wang, Y. Tian, X. Lu, et al., “Pretargeted Mitochondrial Delivery of Organoarsenicals for Cancer Immunotherapy,” Journal of the American Chemical Society 147 (2025): 38534–38548. X. Wen, W. Zeng, J. Zhang, et al., “Cascade in Situ Self‐Assembly and Bioorthogonal Reaction Enable the Enrichment of Photosensitizers and Carbonic Anhydrase Inhibitors for Pretargeted Cancer Theranostics,” Angewandte Chemie International Edition 63 (2024): 202314039. J. Weng, Z. Huang, Y. Liu, et al., “Controlled in Situ Self‐Assembly of Biotinylated Trans‐Cyclooctene Nanoparticles for Orthogonal Dual‐Pretargeted Near‐Infrared Fluorescence and Magnetic Resonance Imaging,” Journal of the American Chemical Society 146 (2024): 13163–13175. F. Chen and M. S. Bradbury, “Engineering Bispecific HER2xVEGF Designed Ankyrin Repeat Proteins for Targeted Nanobiotechnology Applications,” Journal of Nanobiotechnology 23 (2025): 627. B. Hou, J. Ye, L. Huang, et al., “Tumor‐specific Delivery of Clickable Inhibitor for PD‐L1 Degradation and Mitigating Resistance of Radioimmunotherapy,” Science Advances 10 (2024): adq3940. E. Di Ianni, J. Jeon, S. Mohammadi, et al., “Enhanced‐mRNA Delivery Using Ultrasound‐Delivered Anchors for Bioorthogonal Ligation,” Angewandte Chemie International Edition 65 (2026): 23437. Y. Huang, Z. Li, C. Li, et al., “Bioorthogonal Diels–Alder Click Chemistry‐Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death‐Ligand 1 Expression,” ACS Omega 9 (2024): 36969–36981. J. Schwenck, D. Sonanini, J. M. Cotton, et al., “Advances in PET Imaging of Cancer,” Nature Reviews Cancer 23 (2023): 474–490. A. B. Le Roux, E. K. Fung, S. G. Lee, et al., “GPA33‐pretargeted Radioimmunotherapy with Mono‐ and Bivalent DOTA‐based Lu‐177‐labeled Radiohaptens in a Mouse Orthotopic Liver Xenograft Model of Metastatic human Colorectal Cancer,” Theranostics 15 (2025): 6274. C. E. Guerra, P. V. Sharma, and B. S. Castillo, “Multi‐Cancer Early Detection: the New Frontier in Cancer Early Detection,” Annual Review of Medicine 75 (2024): 67–81. F. I. Chinegwundoh, “Prostate Cancer Screening: Better Outcomes from Early Detection,” Bmj 382 (2023): p1842. S. Ma, M. Zhou, Y. Xu, et al., “Clinical Application and Detection Techniques of Liquid Biopsy in Gastric Cancer,” Molecular Cancer 22 (2023): 7. Y. Ando, M. Dbouk, T. Yoshida, et al., “Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN‐2 and Carbohydrate Antigen 19‐9 for Pancreatic Cancer,” Journal of Clinical Oncology 42 (2024): 2196–2206. Y. Zheng, J. Li, B. Zhou, H. Ian, and H. Shao, “Advanced Sensitivity Amplification Strategies for Voltammetric Immunosensors of Tumor Marker: State of the Art,” Biosensors and Bioelectronics 178 (2021): 113021. W. Yan, M. Cao, X. Ruan, et al., “Cancer‐cell‐secreted miR‐122 Suppresses O‐GlcNAcylation to Promote Skeletal Muscle Proteolysis,” Nature Cell Biology 24 (2022): 793–804. A. Robles‐Remacho, I. Martos‐Jamai, M. Tabraue‐Chávez, et al., “Click Chemistry‐based Dual Nanosystem for microRNA‐122 Detection with Single‐base Specificity from Tumour Cells,” Journal of Nanobiotechnology 22 (2024): 791. C. Xu, M. Xu, Y. Hu, et al., “Ingestible Artificial Urinary Biomarker Probes for Urine Test of Gastrointestinal Cancer,” Advanced Materials 36 (2024): 2314084. S. Kumaravel, G. R. Luo, S. T. Huang, H. Y. Lin, C. M. Lin, and Y. C. Lee, “Development of a Novel Latent Electrochemical Molecular Substrate for the Real‐time Monitoring of the Tumor Marker Aminopeptidase N in Live Cells, Whole Blood and Urine,” Biosensors and Bioelectronics 203 (2022): 114049. P. Cheng, Z. Zeng, J. Liu, et al., “Urinary Bioorthogonal Reporters for the Monitoring of the Efficacy of Chemotherapy for Lung Cancer and of Associated Kidney Injury,” Nature Biomedical Engineering 9 (2025): 686–699. F. Yang, H. Zeng, H. Tan, et al., “An LF‐NMR Biosensor for the Detection of Circulating Tumor Cells Based on Target‐Triggered Bioorthogonal Chemistry and Click Chemistry,” Analytical Chemistry 97 (2025): 18110–18116. S. M. Lewis, M.‐L. Asselin‐Labat, Q. Nguyen, et al., “Spatial Omics and Multiplexed Imaging to Explore Cancer Biology,” Nature Methods 18 (2021): 997–1012. X. Ma, M. Mao, J. He, C. Liang, and H. Y. Xie, “Nanoprobe‐based Molecular Imaging for Tumor Stratification,” Chemical Society Reviews 52 (2023): 6447–6496. H. Hricak, M. E. Mayerhoefer, K. Herrmann, et al., “Advances and Challenges in Precision Imaging,” The Lancet Oncology 26 (2025): e34–e45. H. Kang, M. W. Kang, S. Kashiwagi, and H. S. Choi, “NIR Fluorescence Imaging and Treatment for Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 10 (2022): 004936. J. Dai, H. Wang, Y. Xu, X. Chen, and R. Tian, “Clinical Application of AI‐based PET Images in Oncological Patients,” Seminars in Cancer Biology 91 (2023): 124–142. X. Zhou, B. Shi, G. Huang, J. Liu, and W. Wei, “Trends in Cancer Imaging,” Trends in Cancer 10 (2024): 1023–1037. S. Parakh, S. T. Lee, H. K. Gan, and A. M. Scott, “Radiolabeled Antibodies for Cancer Imaging and Therapy,” Cancers 14 (2022): 1454. B. Roohani, A. S. Mendez, M. Dangarwala, S. Katz, and B. Marquez‐Nostra, “Nuclear Imaging of Bispecific Antibodies on the Rise,” Journal of Nuclear Medicine 65 (2024): 1512–1517. W. Hai, X. Bao, K. Sun, B. Li, J. Peng, and Y. Xu, “In Situ Labeling of Pretargeted Hyaluronan for PET/MR Imaging of CD44+ Tumors,” Bioorganic Chemistry 155 (2025): 108110. A. Mishra, A. Carrascal‐Miniño, J. Kim, and R. T. M. de Rosales, “[(68) Ga]Ga‐THP‐tetrazine for Bioorthogonal Click Radiolabelling: Pretargeted PET Imaging of Liposomal Nanomedicines,” RSC Chemical Biology 5 (2024): 622–639. E. C. Pratt, K. Mandleywala, D. Bauer, et al., “Pretargeted Trop‐2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors,” Clinical Cancer Research 31 (2025): 2719–2726. V. Postupalenko, L. Marx, M. Pantin, et al., “Site‐selective Template‐directed Synthesis of Antibody Fc Conjugates with Concomitant Ligand Release,” Chemical Science 15 (2024): 1324–1337. R. Qian, B. Jing, D. Jiang, et al., “Multi‐antitumor Therapy and Synchronous Imaging Monitoring Based on Exosome,” European Journal of Nuclear Medicine and Molecular Imaging 49 (2022): 2668–2681. T. Shi, C. Huang, Y. Li, F. Huang, and S. Yin, “NIR‐II Phototherapy Agents with Aggregation‐induced Emission Characteristics for Tumor Imaging and Therapy,” Biomaterials 285 (2022): 121535. C. Wu, Y. Mao, X. Wang, P. Li, and B. Tang, “Deep‐Tissue Fluorescence Imaging Study of Reactive Oxygen Species in a Tumor Microenvironment,” Analytical Chemistry 94 (2022): 165–176. A. W. McDonagh, B. L. McNeil, J. Rousseau, et al., “Development of a Multi Faceted Platform Containing a Tetrazine, Fluorophore and Chelator: Synthesis, Characterization, Radiolabeling, and Immuno‐SPECT Imaging,” EJNMMI Radiopharmacy and Chemistry 7 (2022): 12. M. Müller, M. Staudt, R. García‐Vázquez, L. Hvass, A. Kjaer, and M. M. Herth, “Synthesis and in Vivo Evaluation of a Polar [(18)F]BODIPY‐Tetrazine as a Pretargeted Bimodal Imaging Agent,” Applied Radiation and Isotopes 225 (2025): 112080. S. Chen, H. Xu, X. Chen, et al., “First‐in‐human Study of a Dual‐modality Prostate‐specific Membrane Antigen–targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer,” European Urology 87 (2025): 717–727. P. Wang, J. Li, M. Wei, et al., “Tumor‐microenvironment Triggered Signal‐to‐noise Boosting Nanoprobes for NIR‐IIb Fluorescence Imaging Guided Tumor Surgery and NIR‐II Photothermal Therapy,” Biomaterials 287 (2022): 121636. F. Wang, L. Qu, F. Ren, et al., “High‐precision Tumor Resection down to Few‐cell Level Guided by NIR‐IIb Molecular Fluorescence Imaging,” Proceedings of the National Academy of Sciences 119 (2022): 2123111119. X. Wang, S. S. Liew, J. Huang, Y. Hu, X. Wei, and K. Pu, “Dual‐Locked Enzyme‐Activatable Bioorthogonal Fluorescence Turn‐On Imaging of Senescent Cancer Cells,” Journal of the American Chemical Society 146 (2024): 22689–22698. Q.‐J. Duan, Z.‐Y. Zhao, Y.‐J. Zhang, et al., “Activatable Fluorescent Probes for Real‐time Imaging‐guided Tumor Therapy,” Advanced Drug Delivery Reviews 196 (2023): 114793. L. J. Lauwerends, P. B. A. A. van Driel, R. J. Baatenburg de Jong, et al., “Real‐time Fluorescence Imaging in Intraoperative Decision Making for Cancer Surgery,” The Lancet Oncology 22 (2021): e186–e195. B. Jing, R. Qian, D. Jiang, et al., “Extracellular Vesicles‐based Pre‐targeting Strategy Enables Multi‐modal Imaging of Orthotopic Colon Cancer and Image‐guided Surgery,” Journal of Nanobiotechnology 19 (2021): 151. I. Tamura, D. M. Sakamoto, B. Yi, et al., “Click3D: Click Reaction across Deep Tissues for Whole‐organ 3D Fluorescence Imaging,” Science Advances 10 (2024): ado8471. G. Lee, S. H. Moon, J. H. Kim, et al., “Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy,” Investigative Radiology 60 (2025): 11–26. S. Khan, M. Falahati, W. C. Cho, et al., “Core–shell Inorganic NP@MOF Nanostructures for Targeted Drug Delivery and Multimodal Imaging‐guided Combination Tumor Treatment,” Advances in Colloid and Interface Science 321 (2023): 103007. X. Shi, K. Gao, G. Zhang, W. Zhang, X. Yang, and R. Gao, “Signal Amplification Pretargeted PET/Fluorescence Imaging Based on Human Serum Albumin‐Encapsulated GdF 3 Nanoparticles for Diagnosis of Ovarian Cancer,” ACS Biomaterials Science & Engineering 8 (2022): 4956–4964. J. M. Pagel, N. Hedin, K. Subbiah, et al., “Comparison of Anti‐CD20 and Anti‐CD45 Antibodies for Conventional and Pretargeted Radioimmunotherapy of B‐cell Lymphomas,” Blood 101 (2003): 2340–2348. H. Li, X. Xiang, L. Guan, et al., “A Peptide Nucleic Acid‐based Pretargeting Approach Using 161Tb for Radionuclide Therapy in a Murine Tumor Model,” EJNMMI Research 16 (2026): 35. R. M. Sharkey, H. Karacay, C. H. Chang, W. J. McBride, I. D. Horak, and D. M. Goldenberg, “Improved Therapy of non‐Hodgkin's Lymphoma Xenografts Using Radionuclides Pretargeted with a New Anti‐CD20 Bispecific Antibody,” Leukemia 19 (2005): 1064–1069. H. Mohsin, F. Jia, J. N. Bryan, et al., “Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using 149Pm, 166Ho, and 177Lu,” Bioconjugate Chemistry 22 (2011): 2444–2452. L. Wang, C. Lynch, S. P. Pitroda, et al., “Radiotherapy and Immunology,” Journal of Experimental Medicine 221 (2024): 20232101. C. Beckers, M. Pruschy, and I. Vetrugno, “Tumor Hypoxia and Radiotherapy: a Major Driver of Resistance Even for Novel Radiotherapy Modalities,” Seminars in Cancer Biology 98 (2024): 19–30. J. M. Price, A. Prabhakaran, and C. M. L. West, “Predicting Tumour Radiosensitivity to Deliver Precision Radiotherapy,” Nature Reviews Clinical Oncology 20 (2023): 83–98. D. Bauer, L. M. Carter, M. I. Atmane, et al., “212 Pb‐Pretargeted Theranostics for Pancreatic Cancer,” Journal of Nuclear Medicine 65 (2024): 109–116. X. Li, X. Lan, and W. Cai, “Pretargeted Radioimmunotherapy of Ovarian Cancer with 225 Ac and an Internalizing Antibody,” Journal of Nuclear Medicine 64 (2023): 1446–1448. S. S. Rinne, D. B. Vargas, B. A. Vaughn, et al., “Comparison of Targeting Two Antigens (GPA33 versus HER2) for 225 Ac‐pretargeted Alpha‐radioimmunotherapy of Colorectal Cancer,” Theranostics 15 (2025): 7489–7500. S. Poty, L. Ordas, Y. Dekempeneer, et al., “Optimizing the Therapeutic Index of sdAb‐Based Radiopharmaceuticals Using Pretargeting,” Journal of Nuclear Medicine 65 (2024): 1564–1570. S. S. Rinne, D. Burnes Vargas, S. Seo, et al., “225Ac α‐Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer,” Journal of Nuclear Medicine 66 (2025): 1714–1721. C. S. Chandler, M. M. Bell, S. K. Chung, et al., “Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis,” Molecular Cancer Therapeutics 21 (2022): 125–137. K. Westerlund, M. Oroujeni, M. Gestin, et al., “Shorter Peptide Nucleic Acid Probes Improve Affibody‐Mediated Peptide Nucleic Acid‐Based Pretargeting,” ACS Pharmacology & Translational Science 7 (2024): 1595–1611. W. Zheng, Y. Wang, X. Wang, et al., “Spatiotemporally Controlled Pretargeted Azide‐functionalized M1 Macrophage‐derived Exosome‐based 68Ga/177Lu Theranostic System for PET Imaging and Targeted Radiotherapy in Breast Cancer,” Biomaterials Advances 181 (2025): 214623. L. Dai, X. Zhang, S. Zhou, et al., “Pretargeted Radiotherapy and Synergistic Treatment of Metastatic, Castration‐resistant Prostate Cancer Using Cross‐linked, PSMA‐targeted Lipoic Acid Nanoparticles,” Journal of Materials Chemistry B 12 (2024): 2324–2333. H. H. Tran, A. Yamaguchi, and H. C. Manning, “Radiotheranostic Landscape: a Review of Clinical and Preclinical Development,” European Journal of Nuclear Medicine and Molecular Imaging 52 (2025): 2685–2709. H. Goto, Y. Shiraishi, and S. Okada, “Continuing Progress in Radioimmunotherapy for Hematologic Malignancies,” Blood Reviews 69 (2025): 101250. M. Ge, X.‐Y. Chen, P. Huang, et al., “Understanding and Overcoming Multidrug Resistance in Cancer,” Nature Reviews Clinical Oncology 22 (2025): 760–780. X. Tang, M. F. Berger, and D. B. Solit, “Precision Oncology: Current and Future Platforms for Treatment Selection,” Trends in Cancer 10 (2024): 781–791. X. Zheng, X. Song, G. Zhu, et al., “Nanomedicine Combats Drug Resistance in Lung Cancer,” Advanced Materials 36 (2024): 2308977. P. K. Chintamaneni, S. K. S. S. Pindiprolu, S. S. Swain, et al., “Conquering Chemoresistance in Pancreatic Cancer: Exploring Novel Drug Therapies and Delivery Approaches amidst Desmoplasia and Hypoxia,” Cancer Letters 588 (2024): 216782. C.‐Y. Kong, Z. Guo, P. Song, et al., “Underlying the Mechanisms of Doxorubicin‐Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death,” International Journal of Biological Sciences 18 (2022): 760–770. D. Li, Y. Yang, S. Wang, et al., “Role of Acetylation in Doxorubicin‐induced Cardiotoxicity,” Redox Biology 46 (2021): 102089. S. Ashrafizaveh, M. Ashrafizadeh, A. Zarrabi, et al., “Long Non‐coding RNAs in the Doxorubicin Resistance of Cancer Cells,” Cancer Letters 508 (2021): 104–114. Y. Santin, K. Formoso, F. Haidar, et al., “Inhalation of Acidic Nanoparticles Prevents Doxorubicin Cardiotoxicity through Improvement of Lysosomal Function,” Theranostics 13 (2023): 5435–5451. H. Duan, Y. Liu, Z. Gao, and W. Huang, “Recent Advances in Drug Delivery Systems for Targeting Cancer Stem Cells,” Acta Pharmaceutica Sinica B 11 (2021): 55–70. E. N. Komedchikova, O. A. Kolesnikova, E. D. Tereshina, et al., “Two‐Step Targeted Drug Delivery via Proteinaceous Barnase‐Barstar Interface and Doxorubicin‐Loaded Nano‐PLGA Outperforms One‐Step Strategy for Targeted Delivery to HER2‐Overexpressing Cells,” Pharmaceutics 15 (2023): 52. V. O. Shipunova, E. N. Komedchikova, P. A. Kotelnikova, M. P. Nikitin, and S. M. Deyev, “Targeted Two‐Step Delivery of Oncotheranostic Nano‐PLGA for HER2‐Positive Tumor Imaging and Therapy in Vivo: Improved Effectiveness Compared to One‐Step Strategy,” Pharmaceutics 15 (2023): 833. S. Srinivasan, N. A. Yee, M. Alečković, et al., “Development of a First‐in‐Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First‐in‐Human Dose Escalation Clinical Trial,” Clinical Cancer Research 31 (2025): 3662–3677. H. L. Wu, H. X. Zhou, L. M. Chen, and S. S. Wang, “Metronomic Chemotherapy in Cancer Treatment: New Wine in an Old Bottle,” Theranostics 14 (2024): 3548–3564. R. Wu, K. Wang, Y. Gai, et al., “Nanomedicine for Renal Cell Carcinoma: Imaging, Treatment and beyond,” Journal of Nanobiotechnology 21 (2023): 3. B. Zheng, Z. Chen, L. Sun, et al., “Intravesical Tumor‐Selective Mucoadhesive Hydrogel for Effective Chemotherapy in Murine Model,” International Journal of Nanomedicine 20 (2025): 7169–7183. C. Xu, R. Song, P. Lu, et al., “<p>a pH‐Responsive Charge‐Reversal Drug Delivery System with Tumor‐Specific Drug Release and ROS Generation for Cancer Therapy</p>,” International Journal of Nanomedicine 15 (2020): 65–80. R. S. Goodman, D. B. Johnson, and J. M. Balko, “Corticosteroids and Cancer Immunotherapy,” Clinical Cancer Research 29 (2023): 2580–2587. F. Märkl, D. Huynh, S. Endres, and S. Kobold, “Utilizing Chemokines in Cancer Immunotherapy,” Trends in Cancer 8 (2022): 670–682. C. Chen, L. Xie, T. Ren, Y. Huang, J. Xu, and W. Guo, “Immunotherapy for Osteosarcoma: Fundamental Mechanism, Rationale, and Recent Breakthroughs,” Cancer Letters 500 (2021): 1–10. M. Singh, V. K. Morris, I. N. Bandey, D. S. Hong, and S. Kopetz, “Advancements in Combining Targeted Therapy and Immunotherapy for Colorectal Cancer,” Trends in Cancer 10 (2024): 598–609. L. Tang, Z. Huang, H. Mei, and Y. Hu, “Immunotherapy in Hematologic Malignancies: Achievements, Challenges and Future Prospects,” Signal Transduction and Targeted Therapy 8 (2023): 306. D. Mandikian, L. Sermeño, R. Ohri, et al., “Effects of Pretargeting and FcRn Binding Abrogation on the Biodistribution of a One‐Armed Antibody‐Based T Cell Imaging Agent,” Bioconjugate Chemistry 36 (2025): 1786–1796. M. Jin, J. Fang, J. Peng, et al., “PD‐1/PD‐L1 Immune Checkpoint Blockade in Breast Cancer: Research Insights and Sensitization Strategies,” Molecular Cancer 23 (2024): 266. W. Cheng, K. Kang, A. Zhao, and Y. Wu, “Dual Blockade Immunotherapy Targeting PD‐1/PD‐L1 and CTLA‐4 in Lung Cancer,” Journal of Hematology & Oncology 17 (2024): 54. H. Zhang, Z. Dai, W. Wu, et al., “Regulatory Mechanisms of Immune Checkpoints PD‐L1 and CTLA‐4 in Cancer,” Journal of Experimental & Clinical Cancer Research 40 (2021): 184. Y. Xu, G. Song, S. Xie, et al., “The Roles of PD‐1/PD‐L1 in the Prognosis and Immunotherapy of Prostate Cancer,” Molecular Therapy 29 (2021): 1958–1969. D. B. Doroshow, S. Bhalla, M. B. Beasley, et al., “PD‐L1 as a Biomarker of Response to Immune‐checkpoint Inhibitors,” Nature Reviews Clinical Oncology 18 (2021): 345–362. C. Gerke, I. Zabala Gutierrez, D. Méndez‐González, et al., “Clickable Albumin Nanoparticles for Pretargeted Drug Delivery toward PD‐L1 Overexpressing Tumors in Combination Immunotherapy,” Bioconjugate Chemistry 33 (2022): 821–828. M. Croft, S. Salek‐Ardakani, and C. F. Ware, “Targeting the TNF and TNFR Superfamilies in Autoimmune Disease and Cancer,” Nature Reviews Drug Discovery 23 (2024): 939–961. J. Huyghe, D. Priem, and M. J. M. Bertrand, “Cell Death Checkpoints in the TNF Pathway,” Trends in Immunology 44 (2023): 628–643. A. J. Freeman, C. J. Kearney, J. Silke, and J. Oliaro, “Unleashing TNF Cytotoxicity to Enhance Cancer Immunotherapy,” Trends in Immunology 42 (2021): 1128–1142. R. Wang, X. Duan, J. Li, C. Zhang, and L. Shen, “Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment,” Clinical Cancer Research 31 (2025): 2294–2308. B. Liu, H. Zhou, L. Tan, K. T. H. Siu, and X. Y. Guan, “Exploring Treatment Options in Cancer: Tumor Treatment Strategies,” Signal Transduction and Targeted Therapy 9 (2024): 175. Y. Gong, X. Hu, M. Chen, and J. Wang, “Recent Progress of Iron‐based Nanomaterials in Gene Delivery and Tumor Gene Therapy,” Journal of Nanobiotechnology 22 (2024): 309. H. Zhang, C. Qin, C. An, et al., “Application of the CRISPR/Cas9‐based Gene Editing Technique in Basic Research, Diagnosis, and Therapy of Cancer,” Molecular Cancer 20 (2021): 126. X. Xu, C. Liu, Y. Wang, et al., “Nanotechnology‐based Delivery of CRISPR/Cas9 for Cancer Treatment,” Advanced Drug Delivery Reviews 176 (2021): 113891. M. van Hees, S. Slott, A. H. Hansen, H. S. Kim, H. P. Ji, and K. Astakhova, “New Approaches to Moderate CRISPR‐Cas9 Activity: Addressing Issues of Cellular Uptake and Endosomal Escape,” Mol Ther 30 (2022): 32. S. Kansız and Y. M. Elçin, “Advanced Liposome and Polymersome‐based Drug Delivery Systems: Considerations for Physicochemical Properties, Targeting Strategies and Stimuli‐sensitive Approaches,” Advances in Colloid and Interface Science 317 (2023): 102930. S. Yang, S. H. Im, J. Y. Chung, et al., “An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer,” Advanced Science 11 (2024): 2308763. R. Yang and J. Cui, “Advances and Applications of RNA Vaccines in Tumor Treatment,” Molecular Cancer 23 (2024): 226. E. Kon, N. Ad‐El, I. Hazan‐Halevy, L. Stotsky‐Oterin, and D. Peer, “Targeting Cancer with mRNA–lipid Nanoparticles: Key Considerations and Future Prospects,” Nature Reviews Clinical Oncology 20 (2023): 739–754. T. Wang, X. Shi, X. Xu, et al., “Emerging Prodrug and Nano‐drug Delivery Strategies for the Detection and Elimination of Senescent Tumor Cells,” Biomaterials 318 (2025): 123129. S. Sheikh, D. Ernst, and A. Keating, “Prodrugs and Prodrug‐activated Systems in Gene Therapy,” Molecular Therapy 29 (2021): 1716–1728. M. H. den Brok, K. E. de Roode, L. H. M. Zijlmans, et al., “Click‐to‐Release for Controlled Immune Cell Activation: Tumor‐Targeted Unmasking of an IL12 Prodrug,” Pharmaceuticals (Basel) 18 (2025): 1380. Y. Teng, D. Wang, Z. Yang, et al., “Bioorthogonal Strategy‐triggered in Situ co‐activation of Aggregation‐induced Emission Photosensitizers and Chemotherapeutic Prodrugs for Boosting Synergistic Chemo‐photodynamic‐immunotherapy,” Biomaterials 317 (2025): 123092. S. Li, J. Pang, Y. Sun, Y. Zhang, and Y. Q. Long, “Conditional Relay Activation of Theranostic Prodrug by Pretargeting Bioorthogonal Trigger and Fluorescence‐Guided Visible Light Irradiation,” Angewandte Chemie International Edition 64 (2025): 202422023. Y. Liu, Q. Zong, Y. Tu, et al., “A Tumor Heterogeneity‐independent Antigen‐responsive Nanocarrier Enabled by Bioorthogonal Pre‐targeting and Click‐activated Self‐immolative Polymer,” Biomaterials 319 (2025): 123200. W. Hu, X. Wang, Y. Feng, et al., “Dual‐Functional Biomimetic Nanoprobes for PET Imaging‐Guided Sonodynamic Therapy and Chemotherapy of Triple‐Negative Breast Cancer,” ACS Applied Materials & Interfaces 17 (2025): 56704–56718. Y. Zhang, C. Qian, C. Chu, et al., “Self‐Assembly of Short Peptides Activates Specific ER‐Phagy and Induces Pyroptosis for Enhanced Tumor Immunotherapy,” Angewandte Chemie International Edition 64 (2025): 202422874. S. Xie, J. Zhu, Y. Peng, et al., “In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy,” Angewandte Chemie International Edition 64 (2025): 202421713. Z. Wang, Q. Wang, H. Cao, et al., “Mitochondrial Localized in Situ Self‐Assembly Reprogramming Tumor Immune and Metabolic Microenvironment for Enhanced Cancer Therapy,” Advanced Materials 36 (2024): 2311043. Y. Zhang, W. Gu, W. Chen, et al., “A Dual‐Targeted Molecule for Disease‐Activatable Proteolysis Targeting Chimeras and Targeted Radionuclide Therapy of Cancer,” Journal of the American Chemical Society 147 (2025): 7897–7907. X. Zhen, L. Jia, Q. Tang, et al., “Hybrid Biointerface Engineering Nanoplatform for Dual‐targeted Tumor Hypoxia Relief and Enhanced Photodynamic Therapy,” Journal of Colloid and Interface Science 647 (2023): 211–223.
Grant Information:	2242031 Beijing Natural Science Foundation; 21801172 National Natural Science Foundation of China
Contributed Indexing:	Keywords: body fluid‐ based detection; in vivo imaging; multitherapy treatment; pre‐targeting strategy; tumor microenvironment heterogeneity
Entry Date(s):	Date Created: 20260919 Date Completed: 20260919 Latest Revision: 20260919
Update Code:	20260920
DOI:	10.1002/mabi.70262
PMID:	42762520
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1616-5195
DOI:	10.1002/mabi.70262